Central Bank & Trust Co. Sells 259 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Central Bank & Trust Co. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,689 shares of the biopharmaceutical company’s stock after selling 259 shares during the quarter. Central Bank & Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $1,203,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Mizuho Securities USA LLC lifted its stake in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP increased its holdings in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after buying an additional 8,949 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the period. Simplify Asset Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at about $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.7 %

NASDAQ:REGN opened at $681.58 on Tuesday. The firm has a market capitalization of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.61 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company’s 50-day simple moving average is $738.60 and its 200 day simple moving average is $948.80.

Analyst Ratings Changes

A number of equities analysts have commented on REGN shares. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.